Press Release
July 23, 2020

Nexelis Acquires Integrated Bioanalytical CRO AIT Bioscience

The Private Equity and Healthcare teams advised Nexelis, a portfolio company of Ampersand Capital Partners, on its acquisition of AIT Bioscience.

With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields. Located in Indianapolis, AIT Bioscience is an integrated bioanalytical laboratory with LC-MS and immunoassay testing capabilities which operates a paperless FDA-inspected facility supported by state-of-the-art electronic systems.

Ampersand is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.

The Goodwin team was led by James Barrett and Ed Amer.

For more details, read the press release.